

TENDER NO. BMSIC/DRUGS/18-04						
Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids						
Company Name <u>NESTOR PHARMACEUTICALS LTD.</u>		Total Number of Pages Submitted in bid documents <u>1</u> TO <u>176</u>				
Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(a)	<b>Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft</b> drawn in Favor of “Managing Director, Bihar Medical Services and Infrastructure Corporation Limited” payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	yes	"11"	yes	
2	3.(b)	Bidder are required to submit <b>Earnest Money Deposit in the form of Demand Draft / Bank Guarantee</b> drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna as follows:- Upto 5 drugs- Rs1,00,000/- (One Lakh only), for 6 to 10 drugs- Rs 2,00,000/- (Two Lakh only), for 11 to 20 drugs- Rs 3,00,000/-(Three Lakh only) and for More than 20 drugs Rs 5,00,000/- (Five Lakh only)	yes	"130"- "128"	yes	
3	3.(c)	Documentary evidence of the <b>constitution of the company/ firm/ Proprietorship such as Memorandum and Articles of Association, Partnership Deed</b> etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	yes	"102"- "47"	yes	
4	3.(d)	The <b>details of Bidder</b> Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	yes	"137"	yes	
5	3.(e)	<b>Power of Attorney or Resolution of Board</b> by which the <b>authorised signatory</b> has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. <b>Format to be used.</b>	yes	–	yes	
6	3.(l)	Copies of the <b>Audited Balance Sheet and Profit and Loss statement</b> showing details of their annual average turnover not less than <b>25 Crores</b> for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). <b>Self-attested copies</b> are to be submitted.	yes	"06"&"04"& "02"	yes	

Archana Singh  
14/11/2018

7	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	yes	"126"- "123"	yes	
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	yes	"17"	yes	
9	3.(q)	Copy of certificate of valid Sales Tax/VAT and GST registration of the bidder company should be submitted (self-attested).	yes	"127"	yes	

  
 Archana Singh  
 14/7/2018



**TENDER NO. BMSIC/DRUGS/18-04**

**Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids**

Company Name: M/s Nestor Pharmaceuticals Ltd.							
Total number of pages submitted in bid documents: 176							
Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks	
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax, Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	137	Yes		
2	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3(e) of the NIT. Format to be used.	Yes	15 & 16	Yes		
3		Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate.	Yes	115-122	Yes		
4		Approved product list as per the license issued for quoted drugs for minimum three years.	Yes	105-115	Yes	Except NIT Sl. No.-91 & 109 not completed three years. For NIT Sl. No. 184 the pharmacopeial specification/ strength not matched	
5		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	105-114	Yes		
6		In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.	NA				
7		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation).	Yes	32-44	Yes	See checklist -III	
8	3.(f)	If permission in Form 46 (For manufacturers) / Form 45 (For Importers) from DCGI has been obtained, then the 3 years manufacturing/ Import & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.	NA				

*R.K. Sharma*  
14.8.18.

9	For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA			
10	FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable	NA			
	NOTE: Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.				
11	3.(g) In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA			
12	3.(h) Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. <b>Self-attested copies</b> are to be submitted.	YES	32-44	YES	
13	3.(i) Non Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted. It should be not more than one year old. <b>Self-attested copies</b> are to be submitted. For Surgicals In case of Non-Drug item "the bidder shall submit an affidavit on Non-Judicial stamp paper stating that the quoted product is not covered under Drugs & Cosmetics Act."	Yes	18-30	Yes	
14	3.(j) WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule-'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. <b>Self-attested copies</b> are to be submitted.	Yes	1	Yes	

*S. K. K...*  
14.7.18



15	3.(k)	Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section. Self-attested copies are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production(Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	Yes	12-14	Yes	
16	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.	Yes	131-132	Yes	Whether Blacklisted or not  No, As per the attached document.
17	3.(o)	List of item quoted in prescribed format as per Annexure-III duly signed.	Yes	103 & 104	Yes	
18	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV.	Yes	9 & 10	Yes	
19	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	134 & 136	Yes	
20	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	15-16	Yes	
21	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	Yes	31	No	
22	Corrigendum point	A Notarized affidavit on a Rs 100/- Non-Judicial Stamp Paper representing that the offered price is the lowest price as compared to the Rates provided to their respective Distributors/ Dealers/ Wholesalers/ Carrying and Forwarding Agents/ Authorized depot sales point in the State of Bihar.	No		No	Not attached in the bids

*S.K. Sharma*  
14.7.18

TENDER NO. BMSIC/DRUGS/18-04													
Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids													
Company name: M/s Nestor Pharmaceuticals Ltd.													
Total number of pages submitted in bid documents: 176													
Sheet to be used for verification of product approval and market standing													
Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic Name	
1	3	Albendazole Tablet IP	i. Brand-ALBEST ii. Albendazole Tablet IP 400 mg	IP 400 mg	IP/400 mg	10 x 10	Not mentioned	Tablet	Tablet	Pg. No.-114 i. Brand Name 08-05-2008 ii. Generic- 09-12-2013	31/12/2022	Brand & Generic	Yes (Pg. No.-34)
2	24	Azithromycin Tablets IP	i. Brand-AZINES-250 mg ii. Azithromycin Dihydrate IP/USP	IP 250 mg	IP/USP/250 mg	10x6	Not mentioned	Tablet	Tablet	Pg. No.-113 i. Brand Name- 21-10-2008 ii. Generic- 09-12-2013	31/12/2022	Brand & Generic	Yes (Pg. No.-38)
3	25	Azithromycin Tablets IP	i. Brand-AZINES-500 mg ii. Azithromycin Dihydrate IP/USP	IP500 mg	IP/USP/500 mg	10x6	Not mentioned	Tablet	Tablet	Pg. No.-113 i. Brand Name- 21-10-2008 ii. Generic- 09-12-2013	31/12/2022	Brand & Generic	Yes (Pg. No.-33)
4	*91	Glimepiride IP Tablet	Glimepiride Tablet IP/BP	IP 2 mg	IP/BP 2mg	10 x 10	Not mentioned	Tablet	Tablet	Pg. No.-112 <b>08-12-2017</b>	31/12/2022	Generic	Yes (Pg. No.-42)
5	103	Ibuprofen Tablet IP	Ibuprofen Tablet IP/BP/USP	IP 200 mg	IP/BP/USP 200 mg	10 x 10	Not mentioned	Tablet	Tablet	Pg. No.-111 25-06-2008	31/12/2022	Generic	Yes (Pg. No.-36)

*R.K. Sharma*  
14.7.18



6	104	Ibuprofen Syrup	Ibuprofen Oral suspension BP	100 mg/5 ml.	IP/ 100 mg/5 ml	60 ml Bottle	Not mentioned	Suspension	Suspension	Pg. No.-110 25-06-2008 & 09-12-2013	31/12/2022	Generic	Yes (Pg. No.-36)
7	108	Iron and Folic Acid Tablet small	Folic Acid & Ferrous sulphate Tablets NFT-III	Each Tablet contains Ferrous Sulphate equivalent to 20 mg of Ferrous element Iron and 100µg Folic Acid (To be labelled as per schedule V)	Each sugar coated tablet contains-Dried Ferrous sulphate IP-67 mg equivalent 20 mg of Ferrous Iron Folic Acid IP-0.1 mg	10 x 10	Not mentioned	Tablet	Tablet	Pg. No.-109 25-06-2008 & 09-12-2013	31/12/2022	Generic	Yes (Pg. No.-36)
8	*109	Iron and Folic Acid Syrup	Iron and Folic Acid Syrup IP (20 mg+0.1 mg)	Elemental Iron 20 mg+ Folic Acid 100 mcg per 5 ml	Each 5 ml contains Ferrous sulphate IP equivalent to elemental Ferrous IRON-20 mg, Folic Acid 0.1mg	60 ml Bottle	Not mentioned	Syrup	Syrup	Pg. No.-108 <b>08-01-2016</b>	31/12/2022	Generic	Yes (Pg. No.-33)
9	119	Levofloxacin Tablet	i. Brand-LEVONES iii. Levofloxacin Tablets-500 mg	500 mg	IP/500 mg	10 x 10	Not mentioned	Tablet	Tablet	Pg.No.- 107 i.Brand Name-16-04-2009 ii. Generic-9-12-2013	31/12/2022	Brand & Generic	Yes (Pg. No.-42)
10	121	Levocetizine Dihydrochloride IP	i. Brand-NESTEX ii. Levocetizine Dihydrochloride IP	5 mg	IP/5 mg	10 x 10	Not mentioned	Tablet	Tablet	Pg.No.-107 i.Brand Name-08-05-2008 ii. Generic-09-12-2013	31/12/2022	Brand & Generic	Yes (Pg. No.-42)
11	166	Ofloxacin Tablet IP	i. Brand-NESTOFLOX Tablet iii. Ofloxacin Tablet IP/USP/200 mg	200 mg	IP/USP/200 mg.	10 x 10	Not mentioned	Tablet	Tablet	Pg.No.- 106 i.Brand Name-22-08-2008 ii. Generic-09-12-2013	31/12/2022	Brand & Generic	Yes (Pg. No.-41)
12	184	Paracetamol Oral suspension IP	Paracetamol Syrup IP	500 mg/ 5 ml	IP 125mg/5 ml	15 ml	Not mentioned	Drop	Syrup	Pg.No.- 105 25-06-2008 & 09-12-2013	31/12/2022	Generic	Yes (Pg. No.-32)

Note:-1. As per NIT sl. No.- \*91 & \*109 -Product approved at 18-01-2016 which is not completed three years.

2. For NIT Sl. No. 184 the pharmacopeial specification/ strength not matched

*R. K. K. K.*  
10.9.18.

## TENDER NO. BMSIC/DRUGS/18-04

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company name: M/s Nestor Pharmaceuticals Ltd.

Total number of pages submitted in bid documents: 176

Sheet for verification of licence details

SL No	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	3	Albendazole Tablet IP	Form 25	224-OSP (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
2	24	Azithromycin Tablets IP	Form 28	94-B (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
3	25	Azithromycin Tablets IP	Form 28	94-B (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
4	*91	Glimepiride IP Tablet	Form 25	224-OSP (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
5	103	Ibuprofen Tablet IP	Form 25	224-OSP (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
6	104	Ibuprofen Syrup	Form 25	224-OSP (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
7	108	Iron and Folic Acid Tablet small	Form 28	94-B (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
8	*109	Iron and Folic Acid Syrup	Form 28	94-B (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)

*P. K. Naraini*  
14.07.18.



9	19	Levofloxacin Tablet	Form 25	224-OSP (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
10	121	Levocetirizine Di-hydrochloride IP	Form 25	224-OSP (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
11	166	Ofloxacin Tablet IP	Form 25	224-OSP (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
12	184	Paracetamol Paediatric Oral suspension	Form 25	224-OSP (H)	-	-	13/09/1979	31/12/2022	01/04/2018	Valid for two years (Pg. no.-1)
<p><b>Note: - Assisted in technical evaluation in reference to letter No-559(15), dated 26.6.2018 on the basis of documents provided by BMSICL in checklist-II, III &amp; IV. Provided checklist compiled with due diligence and care. Inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time, if any discrepancies are observed, for rectification.</b></p>										

*R. K. Sharma*  
14.04.2018.